← Leaderboards
Koen Van De Wetering
Thomas Jefferson University
$1,639,411
Attributed
$3,361,881
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $666K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,361,881 · 3
By mechanism
R01$2,984,361 · 2
R21$377,520 · 1
Top collaborators
- Qiaoli Li5 shared
- Jouni Uitto4 shared
- Makarand V Risbud2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Jouni Uitto$17,268,454
- Qiaoli Li$2,830,040
- Qiujie Jiang$697,740
- Theresa A Freeman$1,916,808
- Mon-Li H. Chu$5,554,728
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesEffective TherapySkinAffectIn VivoMediatingDiphosphatesMineralizationPlasmaCalcificationCardiovascular SystemMorbidity - Disease RateTissuesOralCollaborationsLaboratoriesHigh RiskBlood CirculationHypertensionArteriesCharacteristicsHepatocyteHeritabilityIntermittent Claudication
Grant awards (8)
The role of endogenous low molecular weight mineralization inhibitors in spine health$599,407
R01 · FY2025 · AR · contact PI
The role of endogenous low molecular weight mineralization inhibitors in spine health$666,008
R01 · FY2024 · AR · contact PI
Characterization of ENTPD1 as a drug target in PXE$377,520
R21 · FY2023 · AR · contact PI
Novel Treatments for PXE$337,206
R01 · FY2022 · AR
Novel Treatments for PXE$330,393
R01 · FY2021 · AR
Novel Treatments for PXE$340,613
R01 · FY2020 · AR
Novel Treatments for PXE$348,221
R01 · FY2019 · AR
Novel Treatments for PXE$362,513
R01 · FY2018 · AR